DIFFICULTIES IN DIAGNOSING FABRY DISEASE IN PATIENTS WITH UNEXPLAINED LEFT VENTRICULAR HYPERTROPHY (LVH): IS THE NOVEL GLA GENE MUTATION A PATHOGENIC MUTATION OR POLYMORPHISM?
Aladağ N, Ali Barman H, Şipal A, Akbulut T, Özdemir M, Ceylaner S
*Corresponding Author: Nesim Aladağ, MD, nesimaladag@hotmail.com, Van Yüzüncü yıl University, Faculty of Medicine, Department of Cardiology, Van, Turkey. Phone: +90 544 961 31 69 / Fax: +90 432 486 54 07
page: 43
|
|
REFERENCES
1. Desnick RJ, Brady R, Barranger J, Collins AJ,
Germain DP, Goldman M, et al. Fabry disease, an
under-recognized multisystemic disorder: expert
recommendations for diagnosis, management, and
enzyme replacement therapy. Ann Intern Med. 2003
Feb 18;138(4):338-46. doi: 10.7326/0003-4819-138-
4-200302180-00014.
2. Pinto LL, Vieira TA, Giugliani R, Schwartz IV. Expression
of the disease on female carriers of X-linked
lysosomal disorders: a brief review. Orphanet J Rare
Dis. 2010 May 28;5:14. doi: 10.1186/1750-1172-5-14.
3. Garman SC, Garboczi DN. The molecular defect
leading to Fabry disease: structure of human alphagalactosidase.
J Mol Biol. 2004 Mar 19;337(2):319-
35. doi: 10.1016/j.jmb.2004.01.035.
4. Kampmann C, Baehner F, Whybra C, Martin C,
Wiethoff CM, Ries M, et al. Cardiac manifestations
of Anderson-Fabry disease in heterozygous females.
J Am Coll Cardiol. 2002 Nov 6;40(9):1668-74. doi:
10.1016/s0735-1097(02)02380-x.
5. Mehta A, Ricci R, Widmer U, Dehout F, Garcia
de Lorenzo A, Kampmann C, et al. Fabry disease
defined: baseline clinical manifestations of 366
patients in the Fabry Outcome Survey. Eur J Clin
Invest. 2004 Mar;34(3):236-42. doi: 10.1111/j.1365-
2362.2004.01309.x.
6. Morrissey RP, Philip KJ, Schwarz ER. Cardiac
abnormalities in Anderson-Fabry disease and Fabry’s
cardiomyopathy. Cardiovasc J Afr. 2011 Jan-
Feb;22(1):38-44.
7. Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence
of lysosomal storage disorders. JAMA. 1999
Jan 20;281(3):249-54. doi: 10.1001/jama.281.3.249.
8. Barba-Romero MÁ, Rivera-Gallego A, Pintos-Morell
G; Spanish FOS-Study Group. Fabry disease in
Spain: description of Spanish patients and a comparison
with other European countries using data
from the Fabry Outcome Survey (FOS). Int J Clin
Pract. 2011 Aug;65(8):903-10. doi: 10.1111/j.1742-
1241.2011.02695.x.
9. Linthorst GE, Bouwman MG, Wijburg FA, Aerts JM,
Poorthuis BJ, Hollak CE. Screening for Fabry disease
in high-risk populations: a systematic review. J
Med Genet. 2010 Apr;47(4):217-22. doi: 10.1136/
jmg.2009.072116.
10. Mehta A, Clarke JT, Giugliani R, Elliott P, Linhart
A, Beck M, et al; FOS Investigators. Natural course
of Fabry disease: changing pattern of causes of death
in FOS - Fabry Outcome Survey. J Med Genet. 2009
Aug;46(8):548-52. doi: 10.1136/jmg.2008.065904.
11. Waldek S, Patel MR, Banikazemi M, Lemay R, Lee
P. Life expectancy and cause of death in males and
females with Fabry disease: findings from the Fabry
Registry. Genet Med. 2009 Nov;11(11):790-6. doi:
10.1097/GIM.0b013e3181bb05bb.
12. Nakao S, Takenaka T, Maeda M, Kodama C, Tanaka
A, Tahara M, Yoshida A, Kuriyama M, Hayashibe
H, Sakuraba H, et al. An atypical variant of Fabry’s
disease in men with left ventricular hypertrophy. N
Engl J Med. 1995 Aug 3;333(5):288-93. doi: 10.1056/
NEJM199508033330504.
13. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong
A, Ernande L, et al. Recommendations for
cardiac chamber quantification by echocardiography
in adults: an update from the American Society
of Echocardiography and the European Association
of Cardiovascular Imaging. Eur Heart J Cardiovasc
Imaging. 2015 Mar;16(3):233-70. doi: 10.1093/ehjci/
jev014.
14. Niemann M, Rolfs A, Störk S, Bijnens B, Breunig
F, Beer M, et al. Gene mutations versus clinically
relevant phenotypes: lyso-Gb3 defines Fabry disease.
Circ Cardiovasc Genet. 2014 Feb;7(1):8-16.
doi: 10.1161/CIRCGENETICS.113.000249.
15. Niemann M, Rolfs A, Giese A, Mascher H, Breunig F,
Ertl G, Wanner C, Weidemann F. Lyso-Gb3 Indicates
that the Alpha-Galactosidase A Mutation D313Y is
not Clinically Relevant for Fabry Disease. JIMD Rep.
2013;7:99-102. doi: 10.1007/8904_2012_154.
16. Germain DP. Fabry disease. Orphanet J Rare Dis.
2010 Nov 22;5:30. doi: 10.1186/1750-1172-5-30
17. Chimenti C, Pieroni M, Morgante E, Antuzzi D, Russo
A, Russo MA, et al. Prevalence of Fabry disease in
female patients with late-onset hypertrophic cardiomyopathy.
Circulation. 2004 Aug 31;110(9):1047-53.
doi: 10.1161/01.CIR.0000139847.74101.03.
18. Havndrup O, Christiansen M, Stoevring B, Jensen M,
Hoffman-Bang J, Andersen PS, et al. Fabry disease
mimicking hypertrophic cardiomyopathy: genetic
screening needed for establishing the diagnosis in
women. Eur J Heart Fail. 2010 Jun;12(6):535-40.
doi: 10.1093/eurjhf/hfq073.
19. Sachdev B, Takenaka T, Teraguchi H, Tei C, Lee
P, McKenna WJ, et al. Prevalence of Anderson-
Fabry disease in male patients with late onset
hypertrophic cardiomyopathy. Circulation.
2002 Mar 26;105(12):1407-11. doi: 10.1161/01.
cir.0000012626.81324.38.
20. Ommen SR, Nishimura RA, Edwards WD. Fabry
disease: a mimic for obstructive hypertrophic cardiomyopathy?
Heart. 2003 Aug;89(8):929-30. doi:
10.1136/heart.89.8.929.
21. Monserrat L, Gimeno-Blanes JR, Marín F, Hermida-
Prieto M, García-Honrubia A, Pérez I, et al. Prevalence
of fabry disease in a cohort of 508 unrelated
patients with hypertrophic cardiomyopathy. J Am
Coll Cardiol. 2007 Dec 18;50(25):2399-403. doi:
10.1016/j.jacc.2007.06.062.
22. Elliott P, Baker R, Pasquale F, Quarta G, Ebrahim H,
Mehta AB, et al; ACES study group. Prevalence of
Anderson-Fabry disease in patients with hypertrophic
cardiomyopathy: the European Anderson-Fabry Disease
survey. Heart. 2011 Dec;97(23):1957-60. doi:
10.1136/heartjnl-2011-300364.
23. Hagège AA, Caudron E, Damy T, Roudaut R, Millaire
A, Etchecopar-Chevreuil C, et al; FOCUS study
investigators. Screening patients with hypertrophic
cardiomyopathy for Fabry disease using a filter-paper
test: the FOCUS study. Heart. 2011 Jan;97(2):131-6.
doi: 10.1136/hrt.2010.200188.
24. Mawatari K, Yasukawa H, Oba T, Nagata T, Togawa
T, Tsukimura T, et al. Screening for Fabry disease in
patients with left ventricular hypertrophy. Int J Cardiol.
2013 Aug 10;167(3):1059-61. doi: 10.1016/j.
ijcard.2012.10.076.
25. Terryn W, Deschoenmakere G, De Keyser J, Meersseman
W, Van Biesen W, Wuyts B, et al. Prevalence
of Fabry disease in a predominantly hypertensive
population with left ventricular hypertrophy. Int J
Cardiol. 2013 Sep 10;167(6):2555-60. doi: 10.1016/j.
ijcard.2012.06.069.
26. Palecek T, Honzikova J, Poupetova H, Vlaskova H,
Kuchynka P, Golan L, et al. Prevalence of Fabry disease
in male patients with unexplained left ventricular
hypertrophy in primary cardiology practice: prospective
Fabry cardiomyopathy screening study (FACSS).
J Inherit Metab Dis. 2014 May;37(3):455-60. doi:
10.1007/s10545-013-9659-2.
27. Baptista A, Magalhães P, Leão S, Carvalho S, Mateus
P, Moreira I. Screening for Fabry disease in left
ventricular hypertrophy: documentation of a novel
mutation. Arq Bras Cardiol. 2015 Aug;105(2):139-44.
doi: 10.5935/abc.20150090.
28. Vieitez I, Souto-Rodriguez O, Fernandez-Mosquera
L, San Millan B, Teijeira S, Fernandez-Martin J, et
al. Fabry disease in the Spanish population: observational
study with detection of 77 patients. Orphanet
J Rare Dis. 2018 Apr 10;13(1):52. doi: 10.1186/
s13023-018-0792-8.
29. Maron MS, Xin W, Sims KB, Butler R, Haas TS,
Rowin EJ, et al. Identification of Fabry Disease in a
Tertiary Referral Cohort of Patients with Hypertrophic
Cardiomyopathy. Am J Med. 2018 Feb;131(2):200.
e1-200.e8. doi: 10.1016/j.amjmed.2017.09.010.
30. Kim WS, Kim HS, Shin J, Park JC, Yoo HW, Takenaka
T, et al. Prevalence of Fabry Disease in Korean
Men with Left Ventricular Hypertrophy. J Korean
Med Sci. 2019 Feb 15;34(7):e63. doi: 10.3346/
jkms.2019.34.e63.
31. Oder D, Üçeyler N, Liu D, Hu K, Petritsch B, Sommer
C, et al. Organ manifestations and long-term outcome
of Fabry disease in patients with the GLA haplotype
D313Y. BMJ Open. 2016 Apr 8;6(4):e010422. doi:
10.1136/bmjopen-2015-010422.
32. Branton MH, Schiffmann R, Sabnis SG, Murray
GJ, Quirk JM, Altarescu G, et al. Natural history of
Fabry renal disease: influence of alpha-galactosidase
A activity and genetic mutations on clinical course.
Medicine (Baltimore). 2002 Mar;81(2):122-38. doi:
10.1097/00005792-200203000-00003.
33. Ferreira S, Ortiz A, Germain DP, Viana-Baptista
M, Caldeira-Gomes A, Camprecios M, et al. The
alpha-galactosidase A p.Arg118Cys variant does
not cause a Fabry disease phenotype: data from
individual patients and family studies. Mol Genet
Metab. 2015 Feb;114(2):248-58. doi: 10.1016/j.
ymgme.2014.11.004.
34. Eng CM, Desnick RJ. Molecular basis of Fabry
disease: mutations and polymorphisms in the human
alpha-galactosidase A gene. Hum Mutat.
1994;3(2):103-11. doi: 10.1002/humu.1380030204.
35. Eng CM, Ashley GA, Burgert TS, Enriquez AL,
D’Souza M, Desnick RJ. Fabry disease: thirty-five
mutations in the alpha-galactosidase A gene in patients
with classic and variant phenotypes. Mol Med.
1997 Mar;3(3):174-82.
36. Van der Tol L, Smid BE, Poorthuis BJ, Biegstraaten
M, Deprez RH, Linthorst GE, et al. A systematic
review on screening for Fabry disease: prevalence
of individuals with genetic variants of unknown
significance. J Med Genet. 2014 Jan;51(1):1-9. doi:
10.1136/jmedgenet-2013-101857.
37. Hoffmann B, Beck M, Sunder-Plassmann G, Borsini
W, Ricci R, Mehta A; FOS European Investigators.
Nature and prevalence of pain in Fabry disease and its
response to enzyme replacement therapy--a retrospective
analysis from the Fabry Outcome Survey. Clin
J Pain. 2007 Jul-Aug;23(6):535-42. doi: 10.1097/
AJP.0b013e318074c986.
|
|
|
|
 |
Number 27
VOL. 27 (2), 2024 |
Number 27
VOL. 27 (1), 2024 |
Number 26
Number 26 VOL. 26(2), 2023 All in one |
Number 26
VOL. 26(2), 2023 |
Number 26
VOL. 26, 2023 Supplement |
Number 26
VOL. 26(1), 2023 |
Number 25
VOL. 25(2), 2022 |
Number 25
VOL. 25 (1), 2022 |
Number 24
VOL. 24(2), 2021 |
Number 24
VOL. 24(1), 2021 |
Number 23
VOL. 23(2), 2020 |
Number 22
VOL. 22(2), 2019 |
Number 22
VOL. 22(1), 2019 |
Number 22
VOL. 22, 2019 Supplement |
Number 21
VOL. 21(2), 2018 |
Number 21
VOL. 21 (1), 2018 |
Number 21
VOL. 21, 2018 Supplement |
Number 20
VOL. 20 (2), 2017 |
Number 20
VOL. 20 (1), 2017 |
Number 19
VOL. 19 (2), 2016 |
Number 19
VOL. 19 (1), 2016 |
Number 18
VOL. 18 (2), 2015 |
Number 18
VOL. 18 (1), 2015 |
Number 17
VOL. 17 (2), 2014 |
Number 17
VOL. 17 (1), 2014 |
Number 16
VOL. 16 (2), 2013 |
Number 16
VOL. 16 (1), 2013 |
Number 15
VOL. 15 (2), 2012 |
Number 15
VOL. 15, 2012 Supplement |
Number 15
Vol. 15 (1), 2012 |
Number 14
14 - Vol. 14 (2), 2011 |
Number 14
The 9th Balkan Congress of Medical Genetics |
Number 14
14 - Vol. 14 (1), 2011 |
Number 13
Vol. 13 (2), 2010 |
Number 13
Vol.13 (1), 2010 |
Number 12
Vol.12 (2), 2009 |
Number 12
Vol.12 (1), 2009 |
Number 11
Vol.11 (2),2008 |
Number 11
Vol.11 (1),2008 |
Number 10
Vol.10 (2), 2007 |
Number 10
10 (1),2007 |
Number 9
1&2, 2006 |
Number 9
3&4, 2006 |
Number 8
1&2, 2005 |
Number 8
3&4, 2004 |
Number 7
1&2, 2004 |
Number 6
3&4, 2003 |
Number 6
1&2, 2003 |
Number 5
3&4, 2002 |
Number 5
1&2, 2002 |
Number 4
Vol.3 (4), 2000 |
Number 4
Vol.2 (4), 1999 |
Number 4
Vol.1 (4), 1998 |
Number 4
3&4, 2001 |
Number 4
1&2, 2001 |
Number 3
Vol.3 (3), 2000 |
Number 3
Vol.2 (3), 1999 |
Number 3
Vol.1 (3), 1998 |
Number 2
Vol.3(2), 2000 |
Number 2
Vol.1 (2), 1998 |
Number 2
Vol.2 (2), 1999 |
Number 1
Vol.3 (1), 2000 |
Number 1
Vol.2 (1), 1999 |
Number 1
Vol.1 (1), 1998 |
|
|
